Product Code: 5351
The demulcent eye drops market is predicted to expand substantially through 2030, owing to the growing incidence of DED, glaucoma, and other eye illnesses across the globe. According to World Health Organization estimates of 2021, over 2.2 billion people worldwide suffer from near or distance vision ailment.
Notably, demulcents are mucoprotective substances that minimize irritation and inflammation of the mucous membrane and retain moisture to lubricate the surface of the eye. Inflowing investments by manufacturers and enterprises to enhance the technology to introduce novel OTC demulcent eye drops products will drive the industry growth. Citing an instance, after receiving the FDA clearance for the sale of OTC medications, in February 2021, Alcon, an eye care company, announced the availability of Pataday® Once Daily Relief Extra Strength eye drops at all retail pharmacies in the United States.
Based on type of active pharmaceutical ingredient, the cellulose derivatives segment is expected to occupy over 20% market share by the year 2030. Compared to other available ingredients, manufacturers highly prefer cellulose derivatives owing to their high viscosity and capacity to stay on the ocular surface for an extended period of time. The benefits API in demulcent eye drops to maintain eye moisture is promoting the segmental development.
As per drug formulation, the preservative-based segment is poised to gain traction in the coming years. The Food and Drug Administration mandates the preservatives to be added in multidose formulations to eliminate germs and fungus that might contaminate the liquid in the container over a period of time. The availability of demulcent eye drops with safer preservatives like Polyquad, SofZia, and Purite, which are gentler to the eyes and are available in multidose sterile packaging will boost the segment share.
According to research, prescription medication type segment is slated to generate moderate revenues for the demulcent eye drops industry over the forecast period, owing to the rapid progression of myopia among young children globally. As per the 2020 data by Centers for Disease Control and Prevention (CDC), around 6.8% children under the age of 18 years are diagnosed with eye conditions in the United States.
Speaking of distribution channel, online pharmacies are getting popular among the consumers because of 24x7 service availability and an endless supply of goods. Additionally, compared to local pharmacy stores, online pharmacies provide medicines at lower price and also offer a variety of discounts to promote sales. This, in tandem is estimated to boost the sales of demulcent eye drops through online platforms.
Regionally, LATAM demulcent eye drops market is expected to accumulate significant revenues and grow at over 4.5% CAGR through 2030, on account of huge population base in the region. Furthermore, the growing popularity of medical tourism, which has drawn vast number of people seeking diagnosis and treatment for eye ailments to the LATAM countries will bolster the product demand.
Businesses involved in the production of demulcent eye drops are putting in tactical efforts, including collaborations and product portfolio expansions, to increase their market share. For instance, in May 2022, Alcon announced its plan to acquire EYSUVIS (corticosteroid indicated for short-term treatment of DED) from Kala Pharmaceuticals Inc., a clinical-stage biopharma company. The acquisition will broaden the company's portfolio of ophthalmic eye drops.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Methodology
- 1.2 Base estimates and working
- 1.2.1 North America
- 1.2.2 Europe
- 1.2.3 Asia Pacific
- 1.2.4 Latin America
- 1.2.5 MEA
- 1.3 Forecast parameters
- 1.4 Data validation
- 1.5 Data sources
- 1.5.1 Secondary
- 1.5.1.1 Paid sources
- 1.5.1.2 Unpaid sources
- 1.5.2 Primary
Chapter 2 Executive Summary
- 2.1 Demulcent eye drops industry 360 degree synopsis, 2017 - 2030
- 2.1.1 Business trends
- 2.1.2 Active pharmaceutical ingredient type trends
- 2.1.3 Drug formulation trends
- 2.1.4 Medication type trends
- 2.1.5 Distribution channel trends
- 2.1.6 Regional trends
Chapter 3 Demulcent Eye Drops Industry Insights
- 3.1 Industry segmentation
- 3.2 Industry landscape, 2017 - 2030
- 3.3 Industry impact forces
- 3.3.1 Growth drivers
- 3.3.1.1 Surge in the prevalence of eye diseases
- 3.3.1.2 Innovative drug formulation launches due to advancements in technology
- 3.3.1.3 Growing awareness regarding eye diseases among population base
- 3.3.2 Industry pitfalls & challenges
- 3.3.2.1 Side-effects associated with demulcent eye drops solutions
- 3.3.2.2 Numerous challenges encountered during treatment of various eye diseases
- 3.4 Growth potential analysis
- 3.4.1 By active pharmaceutical ingredient type
- 3.4.2 By drug formulation
- 3.4.3 By medication type
- 3.4.4 By distribution channel
- 3.5 COVID- 19 impact analysis
- 3.6 Industry ecosystem analysis
- 3.6.1 Raw materials and component suppliers
- 3.6.2 Manufacturers
- 3.6.3 Distribution channel analysis
- 3.6.4 End users
- 3.6.5 Vendor matrix
- 3.7 Epidemiological analysis
- 3.8 Pipeline analysis
- 3.9 Technology and innovation landscape, 2021
- 3.10 Regulatory landscape
- 3.10.1 U.S.
- 3.10.2 Europe
- 3.10.3 Asia Pacific
- 3.11 Porter's analysis
- 3.11.1 Bargaining power of suppliers
- 3.11.2 Bargaining power of buyers
- 3.11.3 Threat of new entrants
- 3.11.4 Threat of substitutes
- 3.11.5 Industry rivalry
- 3.12 Competitive landscape, 2021
- 3.12.1 Alcon Inc.
- 3.12.2 Bausch Health Companies Inc.
- 3.12.3 Johnson and Johnson Services, Inc.
- 3.12.4 Company matrix analysis, 2021
- 3.13 PESTEL analysis
Chapter 4 Demulcent Eye Drops Market, By Active Pharmaceutical Ingredient Type
- 4.1 Key segment trends
- 4.2 Cellulose Derivatives
- 4.2.1 Market size, by region, 2017 - 2030 (USD Million)
- 4.3 Dextran 70
- 4.3.1 Market size, by region, 2017 - 2030 (USD Million)
- 4.4 Polyols
- 4.4.1 Market size, by region, 2017 - 2030 (USD Million)
- 4.5 Polymers
- 4.5.1 Market size, by region, 2017 - 2030 (USD Million)
- 4.6 Others
- 4.6.1 Market size, by region, 2017 - 2030 (USD Million)
Chapter 5 Demulcent Eye Drops Market, By Drug Formulation
- 5.1 Key segment trends
- 5.2 Preservative Based
- 5.2.1 Market size, by region, 2017 - 2030 (USD Million)
- 5.3 Non-Preservative Based
- 5.3.1 Market size, by region, 2017 - 2030 (USD Million)
Chapter 6 Demulcent Eye Drops Market, By Medication Type
- 6.1 Key segment trends
- 6.2 Over-the-counter (OTC)
- 6.2.1 Market size, by region, 2017 - 2030 (USD Million)
- 6.3 Prescription
- 6.3.1 Market size, by region, 2017 - 2030 (USD Million)
Chapter 7 Demulcent Eye Drops Market, By Distribution Channel
- 7.1 Key segment trends
- 7.2 Hospital Pharmacies
- 7.2.1 Market size, by region, 2017 - 2030 (USD Million)
- 7.3 Retail Pharmacies
- 7.3.1 Market size, by region, 2017 - 2030 (USD Million)
- 7.4 Online Pharmacies
- 7.4.1 Market size, by region, 2017 - 2030 (USD Million)
Chapter 8 Demulcent Eye Drops Market, By Region
- 8.1 Key regional trends
- 8.2 North America
- 8.2.1 Market size, by country, 2017 - 2030 (USD Million)
- 8.2.2 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
- 8.2.3 Market size, by drug formulation, 2017 - 2030 (USD Million)
- 8.2.4 Market size, by medication type, 2017 - 2030 (USD Million)
- 8.2.5 Market size, by distribution channel, 2017 - 2030 (USD Million)
- 8.2.6 U.S.
- 8.2.6.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
- 8.2.6.2 Market size, by drug formulation, 2017 - 2030 (USD Million)
- 8.2.6.3 Market size, by medication type, 2017 - 2030 (USD Million)
- 8.2.6.4 Market size, by distribution channel, 2017 - 2030 (USD Million)
- 8.2.7 Canada
- 8.2.7.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
- 8.2.7.2 Market size, by drug formulation, 2017 - 2030 (USD Million)
- 8.2.7.3 Market size, by medication type, 2017 - 2030 (USD Million)
- 8.2.7.4 Market size, by distribution channel, 2017 - 2030 (USD Million)
- 8.3 Europe
- 8.3.1 Market size, by country, 2017 - 2030 (USD Million)
- 8.3.2 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
- 8.3.3 Market size, by drug formulation, 2017 - 2030 (USD Million)
- 8.3.4 Market size, by medication type, 2017 - 2030 (USD Million)
- 8.3.5 Market size, by distribution channel, 2017 - 2030 (USD Million)
- 8.3.6 Germany
- 8.3.6.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
- 8.3.6.2 Market size, by drug formulation, 2017 - 2030 (USD Million)
- 8.3.6.3 Market size, by medication type, 2017 - 2030 (USD Million)
- 8.3.6.4 Market size, by distribution channel, 2017 - 2030 (USD Million)
- 8.3.7 UK
- 8.3.7.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
- 8.3.7.2 Market size, by drug formulation, 2017 - 2030 (USD Million)
- 8.3.7.3 Market size, by medication type, 2017 - 2030 (USD Million)
- 8.3.7.4 Market size, by distribution channel, 2017 - 2030 (USD Million)
- 8.3.8 France
- 8.3.8.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
- 8.3.8.2 Market size, by drug formulation, 2017 - 2030 (USD Million)
- 8.3.8.3 Market size, by medication type, 2017 - 2030 (USD Million)
- 8.3.8.4 Market size, by distribution channel, 2017 - 2030 (USD Million)
- 8.3.9 Spain
- 8.3.9.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
- 8.3.9.2 Market size, by drug formulation, 2017 - 2030 (USD Million)
- 8.3.9.3 Market size, by medication type, 2017 - 2030 (USD Million)
- 8.3.9.4 Market size, by distribution channel, 2017 - 2030 (USD Million)
- 8.3.10 Italy
- 8.3.10.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
- 8.3.10.2 Market size, by drug formulation, 2017 - 2030 (USD Million)
- 8.3.10.3 Market size, by medication type, 2017 - 2030 (USD Million)
- 8.3.10.4 Market size, by distribution channel, 2017 - 2030 (USD Million)
- 8.4 Asia Pacific
- 8.4.1 Market size, by country, 2017 - 2030 (USD Million)
- 8.4.2 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
- 8.4.3 Market size, by drug formulation, 2017 - 2030 (USD Million)
- 8.4.4 Market size, by medication type, 2017 - 2030 (USD Million)
- 8.4.5 Market size, by distribution channel, 2017 - 2030 (USD Million)
- 8.4.6 China
- 8.4.6.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
- 8.4.6.2 Market size, by drug formulation, 2017 - 2030 (USD Million)
- 8.4.6.3 Market size, by medication type, 2017 - 2030 (USD Million)
- 8.4.6.4 Market size, by distribution channel, 2017 - 2030 (USD Million)
- 8.4.7 Japan
- 8.4.7.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
- 8.4.7.2 Market size, by drug formulation, 2017 - 2030 (USD Million)
- 8.4.7.3 Market size, by medication type, 2017 - 2030 (USD Million)
- 8.4.7.4 Market size, by distribution channel, 2017 - 2030 (USD Million)
- 8.4.8 India
- 8.4.8.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
- 8.4.8.2 Market size, by drug formulation, 2017 - 2030 (USD Million)
- 8.4.8.3 Market size, by medication type, 2017 - 2030 (USD Million)
- 8.4.8.4 Market size, by distribution channel, 2017 - 2030 (USD Million)
- 8.4.9 Australia
- 8.4.9.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
- 8.4.9.2 Market size, by drug formulation, 2017 - 2030 (USD Million)
- 8.4.9.3 Market size, by medication type, 2017 - 2030 (USD Million)
- 8.4.9.4 Market size, by distribution channel, 2017 - 2030 (USD Million)
- 8.4.10 South Korea
- 8.4.10.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
- 8.4.10.2 Market size, by drug formulation, 2017 - 2030 (USD Million)
- 8.4.10.3 Market size, by medication type, 2017 - 2030 (USD Million)
- 8.4.10.4 Market size, by distribution channel, 2017 - 2030 (USD Million)
- 8.5 Latin America
- 8.5.1 Market size, by country, 2017 - 2030 (USD Million)
- 8.5.2 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
- 8.5.3 Market size, by drug formulation, 2017 - 2030 (USD Million)
- 8.5.4 Market size, by medication type, 2017 - 2030 (USD Million)
- 8.5.5 Market size, by distribution channel, 2017 - 2030 (USD Million)
- 8.5.6 Brazil
- 8.5.6.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
- 8.5.6.2 Market size, by drug formulation, 2017 - 2030 (USD Million)
- 8.5.6.3 Market size, by medication type, 2017 - 2030 (USD Million)
- 8.5.6.4 Market size, by distribution channel, 2017 - 2030 (USD Million)
- 8.5.7 Mexico
- 8.5.7.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
- 8.5.7.2 Market size, by drug formulation, 2017 - 2030 (USD Million)
- 8.5.7.3 Market size, by medication type, 2017 - 2030 (USD Million)
- 8.5.7.4 Market size, by distribution channel, 2017 - 2030 (USD Million)
- 8.6 Middle East & Africa
- 8.6.1 Market size, by country, 2017 - 2030 (USD Million)
- 8.6.2 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
- 8.6.3 Market size, by drug formulation, 2017 - 2030 (USD Million)
- 8.6.4 Market size, by medication type, 2017 - 2030 (USD Million)
- 8.6.5 Market size, by distribution channel, 2017 - 2030 (USD Million)
- 8.6.6 Saudi Arabia
- 8.6.6.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
- 8.6.6.2 Market size, by drug formulation, 2017 - 2030 (USD Million)
- 8.6.6.3 Market size, by medication type, 2017 - 2030 (USD Million)
- 8.6.6.4 Market size, by distribution channel, 2017 - 2030 (USD Million)
- 8.6.7 South Africa
- 8.6.7.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
- 8.6.7.2 Market size, by drug formulation, 2017 - 2030 (USD Million)
- 8.6.7.3 Market size, by medication type, 2017 - 2030 (USD Million)
- 8.6.7.4 Market size, by distribution channel, 2017 - 2030 (USD Million)
- 8.6.8 UAE
- 8.6.8.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)
- 8.6.8.2 Market size, by drug formulation, 2017 - 2030 (USD Million)
- 8.6.8.3 Market size, by medication type, 2017 - 2030 (USD Million)
- 8.6.8.4 Market size, by distribution channel, 2017 - 2030 (USD Million)
Chapter 9 Company Profiles
- 9.1 Competitive dashboard, 2021
- 9.2 Johnson and Johnson Services, Inc.
- 9.2.1 Business overview
- 9.2.2 Financial data
- 9.2.3 Drug formulation landscape
- 9.2.4 Strategic outlook
- 9.2.5 SWOT analysis
- 9.3 Alcon Inc.
- 9.3.1 Business overview
- 9.3.2 Financial data
- 9.3.3 Drug formulation landscape
- 9.3.4 Strategic outlook
- 9.3.5 SWOT analysis
- 9.4 OASIS Medical
- 9.4.1 Business overview
- 9.4.2 Financial data
- 9.4.3 Drug formulation landscape
- 9.4.4 Strategic outlook
- 9.4.5 SWOT analysis
- 9.5 Allergan (AbbVie Inc.)
- 9.5.1 Business overview
- 9.5.2 Financial data
- 9.5.3 Drug formulation landscape
- 9.5.4 Strategic outlook
- 9.5.5 SWOT analysis
- 9.6 Prestige Consumer Healthcare Inc.
- 9.6.1 Business overview
- 9.6.2 Financial data
- 9.6.3 Drug formulation landscape
- 9.6.4 Strategic outlook
- 9.6.5 SWOT analysis
- 9.7 Santen Pharmaceutical Co., Ltd.
- 9.7.1 Business overview
- 9.7.2 Financial data
- 9.7.3 Drug formulation landscape
- 9.7.4 Strategic outlook
- 9.7.5 SWOT analysis
- 9.8 Bausch Health Companies Inc.
- 9.8.1 Business overview
- 9.8.2 Financial data
- 9.8.3 Drug formulation landscape
- 9.8.4 Strategic outlook
- 9.8.5 SWOT analysis
- 9.9 Aurolab
- 9.9.1 Business overview
- 9.9.2 Financial data
- 9.9.3 Drug formulation landscape
- 9.9.4 Strategic outlook
- 9.9.5 SWOT analysis
- 9.10 Otsuka Pharmaceutical Co.,Ltd.
- 9.10.1 Business overview
- 9.10.2 Financial data
- 9.10.3 Drug formulation landscape
- 9.10.4 Strategic outlook
- 9.10.5 SWOT analysis
- 9.11 Sentiss Pharma Pvt. Ltd.
- 9.11.1 Business overview
- 9.11.2 Financial data
- 9.11.3 Drug formulation landscape
- 9.11.4 Strategic outlook
- 9.11.5 SWOT analysis
- 9.12 Sun Pharmaceutical Industries Ltd.
- 9.12.1 Business overview
- 9.12.2 Financial data
- 9.12.3 Drug formulation landscape
- 9.12.4 Strategic outlook
- 9.12.5 SWOT analysis
- 9.13 URSAPHARM Arzneimittel GmbH
- 9.13.1 Business overview
- 9.13.2 Financial data
- 9.13.3 Drug formulation landscape
- 9.13.4 Strategic outlook
- 9.13.5 SWOT analysis